Susan Abushakra, MD
Chief Medical Officer at Alzheon
Alzheon, Inc. operates as a clinical stage biopharmaceutical company. The Company develops treatments for alzheimer’s disease, as well as discovers platform of small molecules for the inhibition of protein misfolding and aggregation in neurodegenerative disorders. Alzheon serves patients worldwide.
Participació
3rd June - 12:50 h.
Plasma Biomarker Effects of ALZ-801 in APOE4 Carriers with Early AD: Phase 2 Study Interim Results - SPEAKER